Richard Pops is the chair and CEO of Alkermes. He is member of the board of directors of Neurocrine Biosciences and Epizyme, both publicly traded biopharmaceutical companies, and also BIO and PhRMA, the industry’s principal advocacy organizations. Alkermes is a fully integrated, global biopharmaceutical company developing innovative medicines in neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders,
...more
